Idiopathic Intracranial Hypertension Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

Idiopathic Intracranial Hypertension Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

Global Idiopathic Intracranial Hypertension Therapeutics Market: About this market

Technavio’s idiopathic intracranial hypertension market analysis considers sales from carbonic anhydrase inhibitors and other drug classes products. Our study also finds the sales of idiopathic intracranial hypertension in Asia, Europe, North America, and ROW. In 2018, the carbonic anhydrase inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as improved vision and decreased intracranial pressure and papilledema will play a significant role in the carbonic anhydrase inhibitors segment to maintain its market position. Also, our global idiopathic intracranial hypertension market report looks at factors such as rising incidences of idiopathic intracranial hypertension, increasing morbidity and mortality rates associated with heart diseases, and identification of risk factors associated with idiopathic intracranial hypertension. However, the asymptomatic nature of disease, limited patient pool, side effects associated with idiopathic intracranial hypertension therapeutics may hamper the growth of the idiopathic intracranial hypertension industry over the forecast period.

Global Idiopathic Intracranial Hypertension Therapeutics Market: Overview

Rising incidences of idiopathic intracranial hypertension

Developed economies such as the US and other countries are witnessing a high incidence of obesity and cardiovascular disorders, which has increased the patient pool for idiopathic intracranial hypertension. This has increased the need for immediate therapeutic interventions such as idiopathic intracranial hypertension therapeutics. Thus, the rising incidence of idiopathic intracranial hypertension will lead to the expansion of the global milk chocolate market at a CAGR of almost 3% during the forecast period.

Increasing number of awareness campaigns.

The global idiopathic intracranial hypertension therapeutics market is expected to benefit from the increasing number of awareness activities that are being undertaken by public and private organizations across the world. For instance, IIH UK, a forum managed by Rare Disease Europe (EURORDIS), helps patients with idiopathic intracranial hypertension in managing their condition. EURORDIS helps increase awareness about rare diseases and focuses on improving the health of patients with rare diseases. The organization conducts specialized social services and facilitates R&D and healthcare policies. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global idiopathic intracranial hypertension market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global idiopathic intracranial hypertension market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading idiopathic intracranial hypertension manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the idiopathic intracranial hypertension market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Vendors: Key offerings
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Carbonic anhydrase inhibitors - Market size and forecast 2018-2023
      • Table Carbonic anhydrase inhibitors - Market size and forecast 2018-2023 ($ millions)
      • Table Carbonic anhydrase inhibitors - Year-over-year growth 2019-2023 (%)
    • Other drug classes - Market size and forecast 2018-2023
      • Table Other drug classes - Market size and forecast 2018-2023 ($ millions)
      • Table Other drug classes - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table Adoption rate of health insurance coverage among US adults with CHD and/or stroke (2019)
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Increasing number of awareness campaigns
    • Rising incidence of rare diseases
    • Special drug designations
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AbbVie Inc.
      • Table AbbVie Inc. - Vendor overview
      • Table AbbVie Inc. - Business segments
      • Table AbbVie Inc. - Organizational developments
      • Table AbbVie Inc. - Geographic focus
      • Table AbbVie Inc. - Key offerings
      • Table AbbVie Inc. - Key customers
    • Astellas Pharma Inc.
      • Table Astellas Pharma Inc. - Vendor overview
      • Table Astellas Pharma Inc. - Business segments
      • Table Astellas Pharma Inc. - Organizational developments
      • Table Astellas Pharma Inc. - Geographic focus
      • Table Astellas Pharma Inc. - Key offerings
      • Table Astellas Pharma Inc. - Key customers
    • Cadila Healthcare Ltd.
      • Table Cadila Healthcare Ltd. - Vendor overview
      • Table Cadila Healthcare Ltd. - Product segments
      • Table Cadila Healthcare Ltd. - Organizational developments
      • Table Cadila Healthcare Ltd. - Geographic focus
      • Table Cadila Healthcare Ltd. - Key offerings
      • Table Cadila Healthcare Ltd. - Key customers
    • Johnson & Johnson Services Inc.
      • Table Johnson & Johnson Services Inc. - Vendor overview
      • Table Johnson & Johnson Services Inc. - Business segments
      • Table Johnson & Johnson Services Inc. - Organizational developments
      • Table Johnson & Johnson Services Inc. - Geographic focus
      • Table Johnson & Johnson Services Inc. - Segment focus
      • Table Johnson & Johnson Services Inc. - Key offerings
      • Table Johnson & Johnson Services Inc. - Key customers
    • Merck & Co. Inc.
      • Table Merck & Co. Inc. - Vendor overview
      • Table Merck & Co. Inc. - Business segments
      • Table Merck & Co. Inc. - Organizational developments
      • Table Merck & Co. Inc. - Geographic focus
      • Table Merck & Co. Inc. - Segment focus
      • Table Merck & Co. Inc. - Key offerings
      • Table Merck & Co. Inc. - Key customers
    • Mylan NV
      • Table Mylan NV - Vendor overview
      • Table Mylan NV - Product segments
      • Table Mylan NV - Organizational developments
      • Table Mylan NV - Geographic focus
      • Table Mylan NV - Segment focus
      • Table Mylan NV - Key offerings
      • Table Mylan NV - Key customers
    • Pfizer Inc.
      • Table Pfizer Inc. - Vendor overview
      • Table Pfizer Inc. - Business segments
      • Table Pfizer Inc. - Organizational developments
      • Table Pfizer Inc. - Geographic focus
      • Table Pfizer Inc. - Segment focus
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Key customers
    • Sanofi
      • Table Sanofi - Vendor overview
      • Table Sanofi - Business segments
      • Table Sanofi - Organizational developments
      • Table Sanofi - Geographic focus
      • Table Sanofi - Segment focus
      • Table Sanofi - Key offerings
      • Table Sanofi - Key customers
    • Sun Pharmaceutical Industries Ltd.
      • Table Sun Pharmaceutical Industries Ltd. - Vendor overview
      • Table Sun Pharmaceutical Industries Ltd. - Business segments
      • Table Sun Pharmaceutical Industries Ltd. - Organizational developments
      • Table Sun Pharmaceutical Industries Ltd. - Geographic focus
      • Table Sun Pharmaceutical Industries Ltd. - Key offerings
      • Table Sun Pharmaceutical Industries Ltd. - Key customers
    • Teva Pharmaceutical Industries Ltd.
      • Table Teva Pharmaceutical Industries Ltd. - Vendor overview
      • Table Teva Pharmaceutical Industries Ltd. - Business segments
      • Table Teva Pharmaceutical Industries Ltd. - Organizational developments
      • Table Teva Pharmaceutical Industries Ltd. - Segment focus
      • Table Teva Pharmaceutical Industries Ltd. - Key offerings
      • Table Teva Pharmaceutical Industries Ltd. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook